Patents by Inventor Shunqi Yan

Shunqi Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glutaminase inhibitors and method of use
    Patent number: 10414740
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 17, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190241523
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Application
    Filed: June 18, 2018
    Publication date: August 8, 2019
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA
    Publication number: 20190169150
    Abstract: The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
    Type: Application
    Filed: February 5, 2019
    Publication date: June 6, 2019
    Inventors: Shunqi YAN, Li-Tain YEH, Robert ORR
  • Therapeutically active compounds and their methods of use
    Patent number: 10294215
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 21, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
    Patent number: 10239854
    Abstract: The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 26, 2019
    Assignee: ARTHROSI THERAPEUTICS, INC.
    Inventors: Shunqi Yan, Li-Tain Yeh, Robert Orr
  • Therapeutic compounds and compositions
    Patent number: 10202339
    Abstract: Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 12, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA
    Publication number: 20190040030
    Abstract: The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
    Type: Application
    Filed: October 4, 2018
    Publication date: February 7, 2019
    Inventors: Shunqi YAN, Li-Tain YEH, Robert ORR
  • GLUTAMINASE INHIBITORS AND METHOD OF USE
    Publication number: 20180370930
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 27, 2018
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • Therapeutic compounds and compositions
    Patent number: 10029987
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 24, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • Glutaminase inhibitors and method of use
    Patent number: 10011574
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: July 3, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • Therapeutically active compositions and their methods of use
    Patent number: 9856279
    Abstract: Provided are piperazine compounds of Formula I useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20170298045
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 19, 2017
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Therapeutically active compounds and their methods of use
    Patent number: 9732062
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: August 15, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
    Publication number: 20170210749
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9708326
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 18, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Shunqi Yan, David J. Loury, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Longcheng Wang
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20170183311
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Application
    Filed: January 23, 2017
    Publication date: June 29, 2017
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
    Patent number: 9662327
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 30, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
  • Therapeutically active compounds and their methods of use
    Patent number: 9656999
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 23, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9580416
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk) having the structure of Formula (B): Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 28, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Shunqi Yan, David J. Loury, Zhaozhong J. Jia, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Gordana Babic Atallah, Riccardo Zanaletti, Maria Pia Catalani, Luca Francesco Raveglia
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20170044139
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang